The recall was initiated due to unacceptable levels of N-nitroso atomoxetine, a possible carcinogen, in multiple batches of the drug, according to a FDA enforcement report.
The affected atomoxetine products, which come in strengths ranging from 10 to 100 milligrams, were manufactured at Glenmark’s facility in Goa, India, and distributed nationwide.
This latest recall adds to a string of product withdrawals by the drugmaker in recent months. In May 2024, the company recalled approximately 47 million capsules of potassium chloride due to dissolution failures. In March 2024, Glenmark also recalled 6,528 bottles of the blood pressure medication diltiazem hydrochloride due to failed dissolution.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
